Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

@inproceedings{Khosravan2016PopulationPM,
  title={Population
Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients
with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor},
  author={Reza Khosravan and Robert J Motzer and Elena Fumagalli and Brian I. Rini},
  booktitle={Clinical pharmacokinetics},
  year={2016}
}
BACKGROUND Sunitinib is a multi-targeted tyrosine kinase inhibitor used in the treatment of advanced renal cell carcinoma (RCC) and imatinib-resistant/intolerant gastrointestinal stromal tumors (GIST). METHODS A meta-analysis of 10 prospective clinical studies in advanced RCC and GIST was performed to support the development of pharmacokinetic (PK) and PK/pharmacodynamic (PD) models that account for the effects of important covariates. These models were used to make predictions with respect… CONTINUE READING